Trial Profile
Phase II randomized trial of neoadjuvant chemotherapeutic treatment (XELOX) followed by chemoradiotherapy (XELOX/RT) and surgery versus chemoradiotherapy followed by surgery and chemotherapy in patients with high risk rectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Jun 2009 Final primary endpoint results presented at the 45th Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2009 Status change from active, no longer recruiting to completed
- 21 Oct 2008 Planned end date changed from 1 Nov 2008 to 1 Nov 2010 as reported by Clinicaltrials.gov.